|

Home
About Diabetes
Complications
Warning Signs
Screening Test
Donate Now
E-Lerts™
Index
Latest News
Diabetes Terms
Health & Fitness
Online Press Center
Meet Mr. Diabetes®
Wake Up And Walk®
Tour
Support Groups
Headlines & Stories
About Us - Contact
Info
Links
| |
Metformin Cuts Risk of
Cancer in Diabetics
posted May 2, 2005
Patients with type 2 diabetes who
are prescribed metformin appear to be at lower risk of cancer than those not
treated with metformin.
Lead author Dr. Josie M. M. Evans and colleagues at the University of Dundee in
Scotland explain that metformin activates the enzyme AMP activated protein
kinase, which in turn is regulated by the tumor suppressor LKB1. They therefore
theorized that metformin use may reduce risk of cancer.
To test their hypothesis, they performed a case-control study in which a
diabetes clinical information system was linked with a database of dispensed
prescriptions.
Between 1993 and 2001, nearly 12,000 patients had been newly diagnosed with type
2 diabetes, including 923 who were later diagnosed with cancer. These were
matched to 1846 diabetic subjects without cancer by age, year of diagnosis and
gender.
During the year prior to the cancer diagnosis, 36.4% of cases and 39.7% of
controls had been given a prescription for metformin (odds ratio 0.86). The odds
ratio for any exposure to metformin since 1993 was 0.79.
There appeared to be a dose-response relationship between metformin and cancer,
as the odds were further reduced by increasing duration of metformin treatment
and total amount of metformin dispensed.
The research team is now in the planning phase of a large cohort study linked to
a cancer registration database, they note.
Source: Diabetes In Control.com: BMJ Online First 2005.
News Article Index
|